false000182867300018286732024-06-142024-06-14

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 14, 2024

 

 

HCW Biologics Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware

001-40591

82-5024477

(State or Other Jurisdiction
of Incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

 

 

 

 

 

2929 N. Commerce Parkway

 

Miramar, Florida

 

33025

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s Telephone Number, Including Area Code: 954 842-2024

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class

 

Trading
Symbol(s)

 


Name of each exchange on which registered

Common Stock, par value $0.0001 per share

 

HCWB

 

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

On June 14, 2024, HCW Biologics Inc. (the “Company”) held its 2024 Annual Meeting of Stockholders (the “Annual Meeting”). At the Annual Meeting, the stockholders voted on the following two proposals and cast their votes as follows:

1.
The Company’s stockholders approved the election of one Class III director to serve for a three-year term expiring at the 2027 Annual Meeting of Stockholders, or until such director's successor is duly elected and qualified or until such director's earlier death, resignation, disqualification or removal:

Nominee

For

Withheld

Broker Non-Votes

Hing C. Wong

24,165,521

1,348,261

2,313,942

The director named under Proposal No. 1 was elected based on the recommendation of the Company's Board of Directors in the Company’s 2024 Proxy Statement.

2.
The Company’s stockholders ratified the appointment of Grant Thornton LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024:

For

Against

Abstain

Broker Non-Votes

27,788,079

7,646

31,999

N/A


 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

 

HCW BIOLOGICS INC.

 

 

 

 

Date:

June 17, 2024

By:

/s/ Hing C. Wong

 

 

 

Hing. C. Wong, Ph.D.
Founder and Chief Executive Officer

 

v3.24.1.1.u2
Document And Entity Information
Jun. 14, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 14, 2024
Entity Registrant Name HCW Biologics Inc.
Entity Central Index Key 0001828673
Entity Emerging Growth Company true
Entity File Number 001-40591
Entity Incorporation, State or Country Code DE
Entity Tax Identification Number 82-5024477
Entity Address, Address Line One 2929 N. Commerce Parkway
Entity Address, City or Town Miramar
Entity Address, State or Province FL
Entity Address, Postal Zip Code 33025
City Area Code 954
Local Phone Number 842-2024
Entity Information, Former Legal or Registered Name Not Applicable
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Ex Transition Period true
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol HCWB
Security Exchange Name NASDAQ
HCW Biologics (NASDAQ:HCWB)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more HCW Biologics Charts.
HCW Biologics (NASDAQ:HCWB)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more HCW Biologics Charts.